SPRY 8-K 2026-11-05

ARS Pharmaceuticals, Inc. (SPRY) 8-K dated 2026-11-05 — accession 0001193125-26-449748.

ARS Pharmaceuticals, Inc. (SPRY) is a biotechnology company listed on NASDAQ.

ARS Pharmaceuticals, Inc. filed a 8-K on 2026-11-05. Accession 0001193125-26-449748.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported SPRY revenue for 2025-12-31 was $84.3M. Net income was -$171.3M. Revenue was down 5.5% from 2024-12-31 to 2025-12-31. SPRY currently screens at market cap $983.1M.

Not investment advice. The SPRY SEC hub lists recent forms. The stock page is the research view.